Guerbet : Q2 2023 sales at the top end of expectations. Guidance unchanged. Management’s tone more positive
>Q2: +6.7% l-f-l (in line with full-year guidance: >5% l-f-l) - Q2 sales were € 198.7m, i.e. +4.6% and +6.7% at cc. At end-June, sales totalled € 378.6m (+2% and +2.8% at cc).By region, note that Asia-Pacific was up 11.6% (+16.6% at cc vs -0.2% in Q1 / market share gain and subsidiary in China and Japan), like Europe which posted an increase of 8.2% and 7.8% at cc. (vs +7.3% in Q1 / price effect and increase in volumes), while America remains under pressure (-15%...Guerbet is a French pharmaceutical group that develops, markets, and provides maintenance services for medical equipment and devices destined for diagnostic and interventional imaging. Co.'s portfolio comprises media solutions covering MRI, X-rays and products devoted to International Radiology and Theranostics and medical devices. Co. organizes its operation by product family covering Magnetic Resonance Imaging (MRI), X-rays (XR) and Interventional Radiology and Theranostics (IRT). The MRI family includes Dotarem® and Artirem®; Co.'s X-ray product family includes Xenetix®, Optiray®/Optiject®, Oxilan®, and Telebrix®; and the IRT product family has Lipiodol®, Bleu Patente V and Hexabrix®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.